Rivastigmine for Alzheimer's disease.

Background: Alzheimer's disease (AD) is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.

Greek validation of the seven-minute screening battery for Alzheimer's disease in the elderly.

The increasing prevalence ofAlzheimer's disease (AD) suggests that there is an increasing need for accurate and easily administered screening instruments. The Seven-Minute Screen is a neurocognitive screening battery consisting of four brief tests (enhanced cued recall, temporal orientation, verbal fluency, and clock drawing). We studied 55 outpatients with probable AD, 40 healthy volunteers of comparable age, sex, and education and 31 elderly patients with other neuropsychological disorders.